False Claims Act & Civil Investigations

Companies in highly regulated industries — particularly in the health care and life sciences space — that receive, or even indirectly benefit from, government expenditures can face sprawling investigations and substantial liability under the False Claims Act. Since 1986, the Department of Justice has collected more than $72 billion in FCA recoveries, netting $2.2 billion in FY 2022 alone. Even a seemingly minor regulatory oversight can snowball into substantial exposure under the FCA’s treble-damages and civil-penalties provisions, or even debarment. That is why companies turn to ArentFox Schiff.

The firm has become a destination for pharma and health care companies facing FCA and other civil investigations and litigation, including qui tam “whistleblower” suits, often involving alleged fraud of government health care programs. The team offers decades of experience in civil and criminal cases, handling everything from responses to subpoenas, civil investigative demands, and internal investigations, to jury, bench, and administrative trials in state and federal forums across the country. Our clients encompass all branches of the health care industry, including pharma, large hospitals, and medical suppliers.